CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer
The crucial role of CD4 + and CD8 + T cells in shaping and controlling immune responses during immune disease and cancer development has been well established and used to achieve marked clinical benefits. CD3 + CD4 - CD8 - double-negative (DN) T cells, although constituting a rare subset of peripher...
Saved in:
Published in | Frontiers in immunology Vol. 13; p. 816005 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
10.02.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The crucial role of CD4
+
and CD8
+
T cells in shaping and controlling immune responses during immune disease and cancer development has been well established and used to achieve marked clinical benefits. CD3
+
CD4
-
CD8
-
double-negative (DN) T cells, although constituting a rare subset of peripheral T cells, are gaining interest for their roles in inflammation, immune disease and cancer. Herein, we comprehensively review the origin, distribution and functions of this unique T cell subgroup. First, we focused on characterizing multifunctional DN T cells in various immune responses. DN regulatory T cells have the capacity to prevent graft-versus-host disease and have therapeutic value for autoimmune disease. T helper-like DN T cells protect against or promote inflammation and virus infection depending on the specific settings and promote certain autoimmune disease. Notably, we clarified the role of DN tumor-infiltrating lymphocytes and outlined the potential for malignant proliferation of DN T cells. Finally, we reviewed the recent advances in the applications of DN T cell-based therapy for cancer. In conclusion, a better understanding of the heterogeneity and functions of DN T cells may help to develop DN T cells as a potential therapeutic tool for inflammation, immune disorders and cancer. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Reviewed by: Laurence Menard, Bristol Myers Squibb, United States; Peter Steinberger, Medical University of Vienna, Austria This article was submitted to Systems Immunology, a section of the journal Frontiers in Immunology Edited by: Peter S. Linsley, Benaroya Research Institute, United States |
ISSN: | 1664-3224 1664-3224 |
DOI: | 10.3389/fimmu.2022.816005 |